Menu Search
Equities

Qlucore AB (publ)

5QO:FRA

Qlucore AB (publ)

Actions
  • Price (EUR)0.458
  • Today's Change-0.01 / -2.14%
  • Shares traded--
  • 1 Year change-42.03%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Qlucore AB is a Sweden-based provider of new generation of intuitive bioinformatics software for research and precision and companion diagnostics. Its mission is to make it easier to analyze the vast amounts of complex data generated by innovations in genomics and proteomics. This is done by providing visualization-based analysis data tools for bioinformatics for research and precision diagnostics. The tools are so easy to use that researchers, technicians and doctors can easily interpret and explore their data sets. Qlucore Diagnostics software is a platform for multi-omics companion and precision diagnostics. AI-driven, disease-specific machine learning-based classification models are combined with patient-friendly visualizations in an easy-to-use and cost-effective software solution that integrates with a wide range of data-generating technologies and instruments. Qlucore was founded in 2007 by researchers at the departments of mathematics and clinical genetics at Lund University.

  • Revenue in SEK (TTM)12.62m
  • Net income in SEK-18.21m
  • Incorporated2006
  • Employees21.00
  • Location
    Qlucore AB (publ)Ideon Science Park, Scheelevagen 17LUND 223 70SwedenSWE
  • Phone+46 462863110
  • Websitehttps://www.qlucore.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.